Stacey Cohen, MD
Hematology & Oncology · Seattle, WANPI 1205099702
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,783 of the $60,756 with a category attached, or 83.6%. 17 manufacturers reported payments, led by GSK at 31.8% of the total. Reporting peaked in 2024 at $26,116 and has fallen 51.1% since, to $12,760 in 2025. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $934.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$19K
- Incyte Corporation$9K
- Regeneron$7K
- Taiho Oncology, Inc.$6K
- Array Biopharma Inc$5K
- AbbVie$3K
- plus $12K from 11 others
Across 74 payments — averaging $24,609 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1M
- Pfizer$466K
- Biontech SE$157K
- EMD Serono, Inc.$100K
- Servier Bioinnovation$51K
- AbbVie$8K
What the payments were for
- Consulting fees$50,78384%
- Speaking & faculty fees$5,1108%
- Travel & lodging$2,8215%
- Food & beverage$2,0343%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $19,300 |
| Incyte Corporation | 14 | $8,943 |
| Regeneron | 9 | $6,897 |
| Taiho Oncology, Inc. | 7 | $5,501 |
| Array Biopharma Inc | 7 | $5,165 |
| AbbVie | 4 | $3,243 |
| Janssen Scientific Affairs, LLC | 3 | $2,715 |
| Merck | 5 | $2,529 |
| Eisai Inc. | 1 | $1,613 |
| Aurobindo Pharma USA, Inc. | 1 | $1,500 |
| Roche Sequencing Solutions, Inc. | 1 | $1,400 |
| Bayer | 1 | $1,283 |
| Intera Oncology, Inc | 1 | $247 |
| Biontech SE | 1 | $166 |
| Pfizer | 1 | $135 |
| Seagen Inc. | 1 | $92 |
| Daiichi Sankyo Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,756 in reported general payments places this provider in the 90th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LoperamideLoperamide Hcl | 28 | $687 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $372 |
| Prochlorperazine Maleate | 15 | $290 |
| Ondansetron Hcl | 15 | $260 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.